Bridge to Life — Valuation, Funding & Investors

Recent changes

Aug 13, 2026Aug 13, 2026Raised $110M Series C Fierce Biotech
Aug 13, 2026Aug 13, 2026Bridge to Life Raises $110M for Organ Preservation Pulse story

Funding History

1 event · sources dated per row

Date	Event	Amount	Valuation	Investors	Source
Aug 13, 2026	Series C	$110M	—		Pulse story

Latest Pulse

Aug 13, 2026Bridge to Life Raises $110M for Organ PreservationBridge to Life closed $110 million in Series C equity funding plus additional debt financing for its organ preservation and perfusion technology, part of a broader wave of biotech capital chasing transplant and longevity-adjacent medtech in 2026.→

Coverage Timeline

newest first

Aug 13, 2026FUNDINGBridge to Life Raises $110M for Organ Preservation$110M Series C→

All Coverage

FUNDING· Aug 13, 2026

Bridge to Life Raises $110M for Organ Preservation

FUNDING$110M Series C

Bridge to Life Raises $110M for Organ Preservation

Bridge to Life closed $110 million in Series C equity funding plus additional debt financing for its organ preservation and perfusion technology, part of a broader wave of biotech capital chasing transplant and longevity-adjacent medtech in 2026.

Aug 13, 2026DEEP DIVE

Related Companies

Same sector

Attovia Therapeutics Apnimed Braveheart Bio Latigo Biotherapeutics Scribe Therapeutics

Sources & methodologyshow

Where these figures come from

Fierce BiotechValue Add VC data1 fact

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data · Suggest a correction